Report library

bb2121

Pipeline product bb2121 (Celgene/bluebird bio) is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), a promising target for immunotherapy which is found in 60–70% of multiple myeloma (MM) patients.

August 9, 2018

Aducanumab

Aducanumab (Biogen/Eisai) is an intravenous-infused, fully human recombinant immunoglobulin G1 monoclonal antibody.

September 29, 2016

Resmetirom

Resmetirom (Madrigal Pharmaceuticals) is a thyroid hormone receptor (THR) β-selective agonist which selectively targets receptors in the liver. The THR is involved in the regulation of metabolism, cholesterol, and triglycerides, as well as the pathological buildup of fat in the liver. The high liver specificity of resmetirom aims to avoid adverse events associated with THR activation outside the liver.

July 22, 2019

Breast Cancer KOL Insight Interview

Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent
change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.

May 8, 2014

Ximency

Ximency (Bristol-Myers Squibb) is a twice-daily fixed-dose combination of daclatasvir, a first-generation NS5A inhibitor; asunaprevir, an NS3 protease inhibitor; and beclabuvir, a non-nucleoside NS5B inhibitor. The combination is approved in Japan for the treatment of genotype 1 (GT-1) chronic hepatitis C virus infection.

November 6, 2017

Market Spotlight: Myelofibrosis

This Market Spotlight report covers the Myelofibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

January 10, 2020

Alunbrig

Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

September 8, 2018

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

MF-59 adjuvanted QIV

CSL’s MF-59 adjuvanted QIV is a subunit, surface antigen-containing seasonal QIV adjuvanted withMF59. It contains antigens from two A strains and two B strains specified by the World HealthOrganization seasonally for seasonal influenza vaccination.

February 2, 2016

Datamonitor Big Pharma Licensing Trends

$3,000.00

This strategy report focuses on Big Pharma Licensing Trends with company analyses, case studies, therapy area analysis, and deal economics.

February 23, 2016

Company Analysis: Merck & Co

$3,000.00

PharmaVitae explores Merck & Co’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

January 25, 2021

Invega Sustenna/Invega Trinza

Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are long-acting injectable formulations developed by Johnson & Johnson, using with Alkermes’s technology.

March 19, 2018

OncoVAX

OncoVAX (Vaccinogen) is a personalized cancer vaccine that uses the patient’s own cancer cells to prevent tumor progression after surgery.

December 11, 2017

Sivextro

Sivextro is a second-generation oxazolidinone, while tedizolid phosphate is a prodrug that is cleaved in the bloodstream to the active antibiotic tedizolid. The active moiety tedizolid inhibits bacterial protein synthesis by interacting with the bacterial 23S ribosome initiation complex.

September 10, 2014

Datamonitor Psoriatic Arthritis KOL Interviews

Datamonitor interviewed three rheumatologists, two based in the US and one in the UK, to determine their current treatment practices and views on pipeline and marketed drugs for psoriatic arthritis. The three interviews were combined into a single report.

December 12, 2016

Entrectinib

Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.

August 30, 2018

Menactra

Menactra (quadrivalent polysaccharide diphtheria toxoid conjugate vaccine; Sanofi) is a quadrivalent polysaccharide diphtheria toxoid conjugate vaccine indicated for active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis (N. meningitidis) serogroups A, C, Y, and W-135 in individuals aged nine months through to 55 years in the US.

September 3, 2019

ITCA 650

ITCA 650 (exenatide; Intarcia Therapeutics/Servier) is a drug-device combination currently being investigated in Phase III trials for the treatment of type 2 diabetes.

November 7, 2017

Nuwiq

Nuwiq (Octapharma) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.

May 4, 2018

Seebri Neohaler

Novartis, under license from Vectura and Sosei, developed Seebri Neohaler, a once-daily inhaled formulation of glycopyrrolate.

July 31, 2018

Datamonitor Healthcare Crohn’s Disease KOL Interviews

Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD.

April 18, 2017

Market Spotlight: Ischemic Stroke

This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

July 20, 2022

Q2 2016 Earnings Previews

$3,000.00

Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.

September 28, 2016

Chronic Myeloid Leukemia (CML) KOL Interview – US, Midwest

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for chronic myeloid leukemia. Disease stratifications by phase, as well as unmet needs, are also discussed. Key pipeline assets highlighted include asciminib, SCO-088, and ASTX030.

August 5, 2021

Human Papillomavirus (HPV) KOL Interview – US, Midwest

A US-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

January 3, 2020

Breo Ellipta

Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

July 31, 2018

Pharma-Payer Partnerships in Emerging Markets

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.

July 26, 2017

Disease Analysis: Acute Myeloid Leukemia (AML)

AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow, which may be derived from either a hematopoietic stem cell or a lineage-specific progenitor cell. “Acute” means that the leukemia may progress rapidly – AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including the lymph nodes, spleen, central nervous system, and testicles.

July 12, 2022

France Healthcare System Overview

France spent more of its gross domestic product (GDP) on healthcare in 2010 than the average of other key developed markets.

November 2, 2016

LixiLan

LixiLan is a once-daily, injectable combination product comprising a fixed ration of Sanofi’s long-lasting basal insulin, Lantus, and glucagon-like peptide-1 (GLP-1) receptor agonist, Lyxumia (lixisenatide).

June 23, 2016

Asthma and COPD KOL Interview

KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.

February 29, 2016

MPC-150-IM

MPC-150-IM (rexlemestrocel-L; Mesoblast) consists of highly purified, immunoselected mesenchymal precursor cells (MPCs).

December 11, 2017

Orenitram

United Therapeutics’ Orenitram (trepostinil) is the first-to-market oral formulation of a prostacyclin analog, and is a reformulation of the company’s intravenous prostacyclin analog Remodulin.

October 19, 2018

Social Media in Pharma

While social media is still relatively new, it has been heralded as one of the most significant changes in the way that people communicate with one another. Despite this, the pharmaceutical industry has been slow to become involved with social media, fearing compliance and regulatory breaches and preferring to stay with the more traditional routes of communication, such as representative visits and emails. However, the growing popularity of social media, combined with a number of positive examples from both within and outside the pharmaceutical industry, has led to an increasing number of pharmaceutical companies looking to grow their social media presence and build on the unique opportunities these platforms offer.

January 27, 2017

Colobreathe

Colobreathe (colistimethate sodium; Allergan) is a dry powder inhaler formulation of the antibiotic colistimethate sodium that is approved for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

September 14, 2017

Zybrestat

Zybrestat (fosbretabulin tromethamine; Mateon Therapeutics) is a water-soluble prodrug of cis-combretastatin A4, originally isolated from the African bush willow (Combretum caffrum).

August 17, 2017

Market Spotlight: Myelofibrosis (MF)

Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.

June 3, 2022

Prostate Cancer KOL Interview – US

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Diagnostic testing and unmet needs are also discussed. Key pipeline assets highlighted include Keytruda, Tecentriq, ipatasertib, DCVAC/PCa, capivasertib, Lutetium 177Lu-PSMA-617, and Cabometyx.

November 10, 2020

Disease Analysis: Prostate Cancer

Prostate cancer occurs when malignant cells originate in the prostate gland. The vast majority of prostate cancers are adenocarcinomas, but other less common types include sarcomas, small cell carcinomas, neuroendocrine tumors, and transitional cell carcinomas. Some prostate cancers can grow and spread quickly, but many are relatively indolent. Because of this, depending on patient age and other co-morbidities, some prostate cancer patients may not receive active treatment for the disease during their lifetime.

June 24, 2022

Market Spotlight: Insomnia

This Market Spotlight report covers the insomnia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

June 23, 2022

European Markets for Spinal Motion-Preserving Devices

$4,850.00

This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the European market for nonfusion spinal technologies for the treatment of degenerative disc disease.

September 22, 2016

Triple-Negative Breast Cancer KOL Interview – UK

A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 31, 2019

Biosimilars Portfolio and Pipeline Trends, 2016

Biosimilars are expected to drive significant cost savings for healthcare systems, yet there are many considerations that will affect the success of biosimilars, ranging from clinical development, regulatory approval, and ongoing legal disputes around patents. In the US, this is still a seminal period, and for that reason the potential effects of biosimilars in terms of levels of competition are still too early to gauge. Still, European experience with biosimilars may give an indication as to how market dynamics will play out and the degree to which biosimilar sponsors may discount their biosimilars in the US.

November 23, 2016

solithromycin

Solithromycin (Cempra Pharmaceuticals/Cubist Pharmaceuticals/Toyama Chemical) is a next-generation ketolide antibiotic. The drug, which is structurally related to the macrolide class of antibiotics, is the first fluoroketolide antibacterial in clinical development for bacterial infections, including CAP.

June 19, 2015